Calcium antagonists: a more expansive role in treating persons with reduced kidney function?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Renin-angiotensin-aldosterone system (RAAS) inhibition with diuretics is often the initial therapy for hypertension in chronic kidney disease (CKD).
• Calcium channel blockers (CCB) were previously less recommended in CKD due to concerns about antiproteinuric effects and renal outcomes compared to RAAS inhibition.

Purpose of the Study:

• To evaluate the expanded role and efficacy of calcium channel blockers (CCB) in managing hypertension in patients with chronic kidney disease (CKD).
• To highlight the safety and effectiveness of CCB in combination therapy for difficult-to-treat CKD hypertension.

Main Methods:

• Review of recent studies on antihypertensive therapies in CKD patients.
• Analysis of comparative efficacy and safety data for RAAS inhibitors versus CCB.
• Assessment of combination therapy outcomes involving CCB and RAAS inhibitors.

Main Results:

• RAAS inhibition with diuretics is a common initial therapy for hypertensive CKD patients.
• CCB efficacy in reducing proteinuria and composite renal outcomes was considered less than RAAS inhibition.
• CCB demonstrated safety and efficacy when used in combination with RAAS inhibitors for CKD hypertension.

Conclusions:

• Despite previous limitations, CCB are finding expanded use in CKD management.
• Combination therapy with CCB and RAAS inhibitors is crucial for achieving target blood pressures in hypertensive CKD patients.
• The safety and efficacy profile supports increased utilization of CCB in this population.